ReviewDiscover oncology2026
Deciphering lncRNA and circRNA control of autophagy in osteosarcoma mechanisms and clinical translation.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is the most common aggressive bone cancer, which predominantly affects children and adolescents. It has high metastatic potential and poor survival in advanced stages. Despite the advancements in multimodal therapy, drug resistance and recurrence remain daunting. Autophagy plays a dual role in OS development-suppressing early tumorigenesis but facilitating the survival of tumor cells under stress. These include major regulators such as non-coding RNAs (ncRNAs), specifically long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs). These ncRNAs regulate autophagy through binding to microRNAs and modulating related signaling pathways. Their dysregulation contributes to OS cell proliferation, metastasis, immune evasion, and chemoresistance. This review summarizes current knowledge on the regulation of autophagy by lncRNAs and circRNAs in OS development. Some are oncogenic drivers that induce autophagy and drug resistance, and others are tumor suppressors that inhibit autophagy and increase drug sensitivity. Some regulatory axes, lncRNA MEG3/miR-21-5p/p53, OIP5-AS1/miR-153/ATG5, Sox2OT-V7/miR-142/miR-22, and circMRPS35/FOXO3, illustrate the complex manner in which ncRNAs affect autophagy and treatment response. Clarification of these networks enlightens OS biology and indicates ncRNAs as potential diagnostic, prognostic, and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.